Last reviewed · How we verify
VSL#3
At a glance
| Generic name | VSL#3 |
|---|---|
| Also known as | Probiotic, probiotic, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis |
| Sponsor | Göteborg University |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy (NA)
- Maternal Probiotic Intervention to Improve Gut Health (PHASE2)
- Probiotic For the Improvement of Environmental Enteropathy in Pregnant Women in Senegal (PHASE2)
- Alcoholic Liver Disease and the Gut Microbiome (NA)
- Intervention on New Onset-T1D Children (NA)
- The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis (PHASE4)
- The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease (NA)
- Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |